poisar

Stocks · News reference

Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

BenzingaAug 21, 2026, 12:42 PMBenzinga Newsdesk

Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 21, 2026, 12:42 PM
Checked
Aug 21, 2026, 12:42 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading